Statera Biopharma, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets (Current Period Unaudited)

In millions of USD, except per-share amounts

	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q3 FY2018 As of Sep 30, 2018	Q2 FY2018 As of Jun 30, 2018	Q1 FY2018 As of Mar 31, 2018	Q4 FY2017 As of Dec 31, 2017
Preferred stock, par value (in dollars per share)
Current assets:
Cash and cash equivalents
Short-term investments
Accounts receivable
Due from subsidiary
Prepaid expenses
Contract asset
Other current assets
Total current assets
Non-current assets:
Operating lease right-of-use assets
Restricted cash
Goodwill
Intangible assets, net
Property and equipment, net
Other long-term assets
Contract asset
Total non-current assets
Assets of discontinued operation
Total assets
Current liabilities:
Accounts payable
Accrued expenses
Accrued warrant liability
Accounts payable and accrued expenses
Current portion of operating lease liabilities
Deferred revenue
Stock issuances due
Notes payable
Advances from related party
Total current liabilities

Non-current liabilities
Non-current liabilities
Commitments and contingencies (Note 9)
Operating lease liabilities, net of current portion
Long-term debt
Total long-term liabilities
Liabilities of discontinued operation
Total liabilities
Stockholders’ equity (deficit):
Preferred stock, $.005 par value; 1,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021
Common stock, $.005 par value; 150,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 50,744,653 shares issued and outstanding as of September 30, 2022 and 35,484,106 shares issued and outstanding as of December 31, 2021
Unadjusted Balance
Total common stock, $.005 par value; 150,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 50,744,653 shares issued and outstanding as of September 30, 2022 and 35,484,106 shares issued and outstanding as of December 31, 2021
Additional paid-in capital
Unadjusted Balance
Total additional paid-in capital
Accumulated other comprehensive income (loss)
Unadjusted Balance
Total accumulated other comprehensive income (loss)
Accumulated deficit
Unadjusted Balance
Total accumulated deficit
Statera Biopharma, Inc. stockholders’ deficit
Unadjusted Balance
Total Statera Biopharma, Inc. stockholders’ deficit
Noncontrolling interest in stockholders’ equity
Unadjusted Balance
Total noncontrolling interest in stockholders’ equity
Stockholders’ deficit
Unadjusted Balance
Total stockholders’ deficit
Total liabilities and stockholders’ deficit

Comments